English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 8 April 2024, 13:45 JST
Share:
    

Source: NEC Corporation
NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines

TOKYO, Apr 8, 2024 - (JCN Newswire) - NEC Corporation (TSE: 6701) has released a white paper, "Towards the realization of AI drug development: Comprehensive process workflow for the commercial use of personalized cancer vaccines". This white paper introduces (1) a comprehensive process workflow that can be applied to a wide range of processes, starting from tumor sample collection to vaccine design, manufacturing, supply, and administration, (2) important perspectives for consideration in the workflow, and (3) advanced technologies that will contribute to the realization of the workflow.

Click here for details and downloads (registration is not required)URL: www.nec.com/en/global/solutions/ai-drug/publication/index.html

NEC is committed to taking on the challenge of realizing new cancer treatments by aiming to establish an accurate, reliable, and comprehensive process workflow that utilizes AI and security technologies.

In recent years, there have been growing expectations for personalized neoantigen cancer vaccines as a next-generation cancer therapy. Personalized neoantigen cancer vaccines are a type of cancer immunotherapy that targets neoantigens containing genomic mutations that are specific to each patient. NEC is working on the realization of personalized cancer vaccines by using one of its core technologies, AI, to identify target neoantigens from each individual patient’s genome data.

This white paper proposes a comprehensive process workflow for personalized cancer vaccines, from design to administration, and the perspectives that should be discussed in this flow. Furthermore, NEC's advanced ICT technologies are introduced to address these perspectives, and the possibility that the use of ICT technology will contribute to the realization of a platform for not only personalized cancer vaccines, but also for various cancer treatments are discussed.

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.



Topic: Press release summary
Source: NEC Corporation

Sectors: MedTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 
NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation Related News
Thursday, 19 December 2024, 12:02 JST
NEC Completes new Asia Pacific submarine cable
Wednesday, 18 December 2024, 17:12 JST
NEC Receives Telecom Review's Global Excellence Award for Innovative Telecom B2B/ Enterprise Network Solutions
Thursday, 12 December 2024, 16:27 JST
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1, an AI-Driven Personalized Oral Cancer Vaccine, at ESMO Immuno-Oncology Congress 2024
Monday, 9 December 2024, 14:06 JST
NEC begins sale of 100G QSFP28 ZR4 single-fiber bi-directional optical transceiver
Friday, 29 November 2024, 15:27 JST
JAL and NEC Test AI-Powered Carry-On Baggage Analysis Solution
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575